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 Abstract 
  Aim:   To investigate the use of drugs with anticholinergic properties (DAPs) and their associa-
tions with delirium and mortality among elderly patients with comorbidities.   Methods:   425 
patients ( 6 70 years of age) in geriatric wards and nursing homes were assessed. The use of DAPs 
was retrieved from their medical records. Delirium was diagnosed according to the DSM-IV cri-
teria.   Results:   Of the 341 patients (80.2%) treated with multiple DAPs (  6  2), 92 patients (27.0%) 
suffered from delirium, whereas 14 of 84 patients (16.7%) without DAP treatment had delirium
(p = 0.050). In a logistic regression analysis with age, gender, and Charlson Comorbidity Index 
as covariates, DAP treatment did not predict delirium (odds ratio 1.67, 95% confidence interval 
0.87–3.21). The 2-year mortality was 49.3% (n = 168) in DAP users and 35.7% (n = 30) in non-users, 
respectively (p = 0.026). In the Cox proportional hazard model adjusted for age, gender, and 
comorbidity, DAPs did not predict mortality (hazard ratio 1.12, 95% confidence interval 0.75–
1.68).   Conclusion:   The use of DAPs is very frequent among frail inpatients with comorbidities, 
but their use has no independent prognostic significance.    Copyright © 2011 S. Karger AG, Basel 
  Published online: January 19, 2011     
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 Introduction 
  Delirium is a common clinical problem in elderly patients in hospitals and in nursing 
home residents. Its prevalence varies from 1 to 56%, depending on the population studied  [1]  
and the diagnostic tools and criteria chosen   [2]  . The etiology of geriatric delirium is multi-
factorial. It consists of predisposing factors adding to patients’ baseline vulnerability (e.g. 
dementia) and precipitating (noxious) factors (e.g. major surgery), which may lead to deliri-
um in complex interaction   [3, 4]  . Delirium prolongs hospital stay   [5]  , increases the need of 
care, and is associated with increased mortality   [6]  .
  While cognitive impairment is one of the major factors predisposing to delirium  [7] , ad-
verse effects of drugs may be an important precipitating factor  [4, 8] . Experimental and clin-
ical studies have shown that in a vulnerable person delirium can be induced by treatment 
with scopolamine, an anticholinergic drug, and it can be reversed with physostigmine, a po-
tent cholinomimetic drug   [9]  . It has been demonstrated that regular use of drugs with anti-
cholinergic properties (DAPs) can cause cognitive decline in older individuals   [10–13]  .
    Characteristic symptoms of delirium are supposed to be mediated by acetylcholine de-
ficiency and dopamine excess, both in absolute amounts and/or relative to each other   [14, 
15 ]  . Many commonly prescribed as well as over-the-counter drugs have anticholinergic 
properties of varying degree. It is thus of clinical interest to clarify whether the use of DAPs 
is associated with delirium and poor outcome in elderly patients, especially in those with 
dementia.
    This study has three aims: (1) to investigate the use of DAPs in elderly patients with co-
morbidities in acute geriatric wards and nursing home residents; (2) to clarify the relation-
ship between the use of DAPs and delirium, and (3) to study the prognostic significance of 
DAPs regarding mortality.
  Material  and  Methods 
  This study was originally designed to assess the phenomenology of delirium   [16]  . The 
database included detailed assessments of all eligible patients in 7 acute wards of 2 geriatric 
hospitals, and of residents in 13 wards of 7 nursing homes in Helsinki, Finland. Representa-
tive, average-sized nursing homes were chosen for the study. After a complete description of 
the study had been provided, all individuals who had given informed consent were included 
in the study, and in those with a poor capacity for judgment, informed consent was obtained 
from the patients’ closest proxy. The only exclusion criteria were age  ! 70 years and/or coma.
    All the patients in geriatric wards and the residents in nursing homes underwent thor-
ough assessments to detect delirium and preexisting dementia. The study subjects were 
  assessed using an extensive questionnaire including mental and cognitive tests, such as the 
Mini-Mental State Examination (MMSE), a 30-point test assessing global cognitive func-
tion   [17]  ; Digit Span, a test of working memory and attention, in which the patient repeats 
a series of random digits forward and backward   [18]  ; the Clinical Dementia Rating (CDR) 
scale, a 5-point scale in which a value of 0 denotes no cognitive impairment and the remain-
ing 4 categories indicate various stages of dementia   [19]  ; and the proverb part (testing ab-
stract thinking and judgment) of the Wechsler Adult Intelligence Scale, the most common-
ly used intelligence scale for adults  [20] . The assessment also included background informa-
tion on the patient, such as demographic variables, diagnoses, and alcohol and tobacco use. 
All available medical records and nurses’ notes both in the acute geriatric wards and in the 
nursing homes were reviewed by one of two skilled and experienced geriatricians (J.V.L. and 
K.H.P.) to obtain as much information as possible on medical history, acute medical prob-45
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lems, current diagnoses, and medication use, as well as to acquire information on symptoms 
and signs prior to the interview. Delirium was defined using the DSM-IV   [21]  . The criteria 
for delirium according to the DSM-IV were operationalized to simple yes/no questions and 
included in a questionnaire.
    To enhance the accuracy of the patients’ preexisting dementia diagnoses we re-evaluat-
ed them and based the dementia diagnoses in this study on global judgment (definite or 
probable) of three geriatricians (J.V.L., K.H.P., and T.E.S.) with the aid of the following infor-
mation: (1) existing dementia diagnoses were evaluated; (2) the CDR scale   [19]   and the op-
erationalized DSM-IV criteria for dementia served to support the diagnoses; (3) nurses and/
or caregivers were interviewed about the earlier cognitive performance and physical func-
tioning of the patient; (4) results of brain computerized tomography/magnetic resonance 
imaging (36% of the patients), electroencephalography (3% of the patients), and the previous 
MMSE scores (32.5% of the patients) were registered if available. All medical diagnoses were 
retrieved from the patients’ records and confirmed by the study geriatricians. Comorbidity 
was computed for each resident using the Charlson Comorbidity Index  [22] , a weighted index 
that takes into account the number and the seriousness of a resident’s comorbid diseases. It 
has been shown to be a valid measure of prognosis in older people   [22]  . 
  Dependence on caregivers in activities of daily living was assessed according to the CDR 
scale item ‘personal care’   [19]  : CDR class 1 or higher (‘requiring at least prompting or assis-
tance in dressing, hygiene, managing personal effects, or requiring much help with person-
al care, often involving incontinence’) was defined as activities of daily living dependence.
    Every medication of each patient was retrieved from medical records. We assessed the 
participants’ use of DAPs as follows: they were listed according to previous scientific litera-
ture   [10, 23–27]   (  table 1  ). Only the DAPs used in a regular daily sequence were registered. In 
order to confirm a significant anticholinergic effect, participants were divided into two 
groups according to their DAP use: subjects receiving   6  2 DAPs and   !  2 DAPs. Mortality 
data were retrieved from central registers, and the follow-up was complete for 100% of the 
Table 1.   DAPs according to our previous study [27] and further relevant literature [10, 23, 24, 25, 26, 28]
High anticholinergic properties Detectable anticholinergic properties
Amitriptyline [10, 25, 26, 27] Disopyramide [25, 26, 27]
Clidinium [26, 27] Flupentixole [26, 27]
Emepronium [27] Furosemide [10, 27]
Hydroxyzine [10, 25, 27, 28] Ipratropium bromide [25, 27]
Levomepromazine [10, 26, 27] Isosorbide mono-/dinitrate [25, 27]
Orphenadrine [27] Metoclopramide [27, 28]
Oxybutynine [10, 25, 27, 28] Nifedipine [25, 27]
Periciazine [27] Olanzapine [27]
Perphenazine [26, 27]
Detectable anticholinergic properties Pilocarpine [24]
Alprazolam [10, 27] Prochlorperazine [27]
Biperidine [25, 27] Quinidine [25, 27]
Captopril [25, 27] Ranitidine [25, 27]
Chlorpromazine [10, 27] Theophylline [10, 25, 27]
Clomipramine [10, 25, 27] Thioridazine [25, 27]
Codeine [10, 25, 27] Tolterodine [27]
Corticosteroids [25, 27] Triamterene [27]
Diazepam [27, 28] Tramadol [27]
Digoxin [10, 25, 27] Trimipramine [10, 25, 27]
Doxepine [25, 26, 27, 28] Warfarin [25, 27]
Dipyridamole [25, 27, 28]46
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patients. The study was approved by the local ethics committees (the Ethics Committee of 
the Department of Medicine, Helsinki University Hospital, and the Helsinki City Ethics 
Committee).
  Statistical  Analysis 
  Differences between users and non-users of DAPs were compared using the     2   test for 
categorical variables and the Mann-Whitney U test for continuous variables. We used logis-
tic regression [odds ratios (OR) with 95% confidence intervals (CI)] analysis to test the inde-
pendent association of the use of DAPs with delirium. Age, gender and Charlson Comorbid-
ity Index were used as covariates. Cox proportional hazards analysis was used to model the 
prognostic significance of the use of DAPs on the risk of mortality [hazard ratio (HR) with 
95% CI]. The model was adjusted for age, gender, and Charlson Comorbidity Index. All data 
were analyzed using the NCSS statistical program for Windows (NCSS, Kaysville, Utah, 
USA). Results were considered statistically significant at a level of p   ^   0.05.
  R e s u l t s  
  Among the 425 patients (women 81.6%, n = 347), 230 were treated in acute geriatric 
wards and 195 were nursing home residents. The mean age of the study participants was 86.1 
years [standard deviation (SD) 7.0;   table 2  ].
  Among all patients, 80.2% (n = 341) used at least 2 DAPs daily. The most frequently used 
DAPs were furosemide, isosorbide nitrate, digoxin, tramadol, dipyridamole, warfarin, tri-
amterene, and prednisone (  table 3  ). DAP users were older, had a higher number of comor-
bidities and consumed more drugs. Among all DAP users, 27.0% (n = 92) were suffering from 
delirium at the time of the interview compared with 16.7% (n = 14) of the non-users (p = 
0.050). In a logistic regression analysis with age, gender, and Charlson Comorbidity Index as 
covariates, the use of DAPs did not predict delirium (OR 1.67, 95% CI 0.87–3.21). Among pa-
Table 2.   Demographic characteristics of the study population divided by the use of DAPs (n = 425)
DAP user (≥2)
(n = 341)
DAP user (<2)
(n = 84)
p value1
Mean age, years (SD) 86.7 (6.8) 83.7 (7.2) <0.001
Female, % 83.0 76.2 0.15
Primary school or less, % 52.4 52.2 0.99
Widowed, % 56.1 46.8 0.14
Dependent in activities of daily living, %2 74.9 83.1 0.11
Mean MMSE (SD) 13.3 (7.9) 11.3 (7.6) 0.045
Mean number of medications (SD) 8.9 (3.0) 6.1 (3.1) <0.001
Mean Charlson Comorbidity Index (SD) 2.4 (1.6) 1.5 (1.2) <0.001
Dementia, % 57.2 71.4 0.017
Delirium by DSM-IV, % 27.0 16.7 0.050
Residence at the time of assessment, %
Acute geriatric ward (n = 230)
Nursing home (n = 195)
56.9
43.1
42.9
57.1
0.021
2-year mortality, % 49.3 35.7 0.026
1 Differences between the groups were tested by 2 test for categorical variables and by Mann-Whitney 
U test for non-normally distributed continuous variables. 2 Based on a CDR ‘personal care’ >1 [19].47
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tients with prior dementia (n = 255), delirium was found in 28.7% (n = 56) of DAP users and 
16.7% (n = 10) of non-users (p = 0.062).
    Of the whole study population, 46.6% (n = 198) died within 2 years. The all-cause mor-
tality was 49.3% (n = 168) in DAP users and 35.7% (n = 30) in non-users (p = 0.026;   table 2  ). 
In the Cox proportional hazard model, Charlson Comorbidity Index (HR 1.18, 95% CI 1.08–
1.29; p   !   0.001), age (HR 1.06/year, 95% CI 1.04–1.08; p   !   0.001) and male gender (HR 1.55, 
95% CI 1.09–2.20; p = 0.014) were independently associated with mortality, whilst the use of 
DAPs was no longer an independent predictor (HR 1.12, 95% CI 0.75–1.68; p = 0.56).
    Among dementia patients, the mortality rates were 50.8% (n = 99) and 31.7% (n = 19) 
among DAP users and non-users, respectively (p = 0.009). In patients with dementia, the use 
of DAPs did not predict mortality in the Cox proportional hazard model with age, gender, 
and Charlson Comorbidity Index as covariates (HR 1.41, 95% CI 0.85–2.34).
  The use of DAPs did not emerge as a significant prognostic factor in any subgroup anal-
ysis (patients admitted to acute geriatric wards, nursing home residents, persons with or 
without dementia, and patients   1  85 or   !  85 years of age). We also tested whether a cutoff 
point of   1  3 DAPs would strengthen the association: the 2-year mortality was 58 and 43%
(p = 0.006), and the delirium prevalence was 25 and 25% (p = 0.94) among users (  1 3  DAPs) 
and non-users (  !  3 DAPs), respectively.
  Discussion 
  The use of multiple DAPs was very frequent in this elderly, frail population since we in-
cluded all drugs defined as having anticholinergic properties in our list. Bivariate analyses 
suggested that the use of DAPs increased the risk for both delirium and mortality. However, 
in multivariate analyses, the associations were no longer significant.
  It is important to recognize that many drugs in daily long-term use have anticholinergic 
properties and that the use of DAPs cannot be fully avoided. In fact, over 80% of the patients 
in our study were using multiple DAPs as part of their everyday medication. Many of these 
drugs are essential for cardiovascular patients, drugs like furosemide, isosorbide nitrate, di-
goxin, triamterene or warfarin cannot be simply withdrawn or replaced. In another study by 
our group, prednisone and tramadol were assessed to be the most common precipitating 
drugs for delirium   [4]  , and these drugs are also often required. However, there were also 
many DAPs, such as hydroxyzine, oxybutynine, doxepine, diazepam and metoclopramide, 
which are considered inappropriate for older people   [28]  .
Table 3.   The 24 most frequently used drugs and numbers of users
Furosemide 152 Amitriptyline 13
Isosorbide nitrate 115 Codeine 12
Digoxin 101 Theophylline 10
Tramadol 53 Nifedipine 10
Dipyridamole 34 Tolterodine 9
Warfarin 31 Biperidine 9
Triamterene 22 Pilocarpine 8
Prednisone 22 Diazepam 8
Hydroxyzine 16 Alprazolam 7
Oxybutynine 15 Doxepine 7
Periciazine 14 Captopril 7
Ipratropium bromide 14 Metoclopramide 648
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    DAP users were older and had more often comorbid disease, and they used more drugs 
than the non-users. Therefore, the higher prevalence of delirium and the worse prognosis 
among the DAP users compared with the non-users was expected. However, we failed to 
show an independent prognostic significance for DAP use in this population. For several 
reasons, the negative results should be interpreted with caution. Firstly, almost all subjects 
used at least 1 DAP and neither the short-term nor the long-term anticholinergic effect
could be quantified in this setting. Secondly, DAPs are only one of the precipitating factors 
for delirium   [4, 8]   and their influence may be masked by other triggers, such as infections 
and metabolic disorders. Due to the large number of predisposing and precipitating factors 
for delirium   [4]  , it is challenging to show an independent role for any single factor, for ex-
ample DAPs, in cross-sectional studies. Thirdly, the statistical power of our study may not 
be sufficient to show differences between the groups, although this is one of the largest stud-
ies conducted on this topic. With a 5% type I error and 80% power, approximately 288 pa-
tients in each group would have been needed to show a 10% difference.
    Interestingly, the use of DAPs was more prevalent among patients without dementia 
compared to those with dementia. Therefore, the MMSE scores were also somewhat higher 
among DAP users. A large proportion of the patients with dementia resided in a nursing 
home, where physicians often tend to reduce DAPs because of hypotension, terminal stage, 
or dementia. We also know that doctors in these settings tend to avoid prescribing DAPs to 
patients with dementia in the first place. Therefore, it is notable that our sample included 
patients both in acute geriatric wards (prevalence of delirium 35%   [2]  ) as well as in nursing 
homes (prevalence of delirium 14%). On the other hand, nursing home residents had a high-
er prevalence of dementia and, therefore, were more vulnerable to DAPs. In Finland, most of 
the acute care of nursing home residents takes place in nursing homes; thus, a heterogeneous 
patient cohort could be studied.
    Our results do not confirm the results of a previous study suggesting an association be-
tween DAPs and excess mortality   [29]  . However, that study involved a highly selected popu-
lation of hip fracture patients, and its results cannot be compared with our cohort or a gen-
eral older population.
    The strengths of our study include the following issues: the study population represent-
ed the clinical reality well and included a fairly large number of patients with delirium. The 
data were carefully collected, including the prompt documentation of confirmed diagnoses 
and medications used. The procedures to diagnose dementia and delirium were appropriate, 
and the 2-year follow-up was complete for 100% of the patients.
    A limitation of our study is its cross-sectional nature concerning the use of DAPs. Be-
cause it was not randomized according to the use of DAPs, all confounding factors could not 
be controlled for. DAPs may also vary in their anticholinergic properties, and individual re-
sponses may vary, too   [30]  . These could not be measured in our study; however, their effect 
was minimized by setting the cutoff point to   6  2 DAPs to ensure a significant anticholiner-
gic effect. So far, there is no international consensus on the list of DAPs and the levels of their 
anticholinergic effect, especially among elderly vulnerable patients   [13, 27, 31]  . The list of 
DAPs varies considerably among countries. We used a list of DAPs which we have previ-
ously shown to be associated with cognitive decline among older persons   [27]  .
    While we did not find a correlation between increased mortality or increased incidence 
of delirium and DAP treatment, we think that further studies on other potential adverse ef-
fects as well as the overall effect of DAPs on older patients are required. These medications 
should be used with caution and at a minimum dosage, especially in patients with comor-
bidities or dementia.
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